| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.31M | 10.92M | 12.31M | 8.70M | 6.55M | 7.82M |
| Gross Profit | 10.45M | 9.31M | 10.57M | 7.35M | 5.86M | 6.29M |
| EBITDA | 871.00K | 183.00K | 643.00K | -38.00K | -305.00K | 69.00K |
| Net Income | 414.00K | -158.00K | 309.00K | -338.00K | -642.00K | -322.00K |
Balance Sheet | ||||||
| Total Assets | 4.82M | 4.43M | 5.21M | 4.13M | 4.26M | 3.82M |
| Cash, Cash Equivalents and Short-Term Investments | 174.00K | 236.00K | 765.00K | 50.00K | 459.00K | 367.00K |
| Total Debt | 309.00K | 619.00K | 439.00K | 1.46M | 1.70M | 1.07M |
| Total Liabilities | 2.98M | 3.15M | 3.83M | 3.46M | 3.43M | 2.72M |
| Stockholders Equity | 1.84M | 1.28M | 1.38M | 670.00K | 836.00K | 1.11M |
Cash Flow | ||||||
| Free Cash Flow | 1.25M | -29.00K | 1.67M | -98.00K | -501.00K | 450.00K |
| Operating Cash Flow | 1.28M | 21.00K | 1.71M | -33.00K | -446.00K | 515.00K |
| Investing Cash Flow | -30.00K | -73.00K | -43.00K | -116.00K | -69.00K | -88.00K |
| Financing Cash Flow | -1.13M | -477.00K | -954.00K | -260.00K | 607.00K | -492.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | £52.38M | 13.87 | 44.68% | ― | 1.44% | ― | |
71 Outperform | £36.40M | 16.20 | 6.45% | 3.35% | 2.40% | 1101.69% | |
70 Outperform | £12.18M | 6.89 | 23.32% | 6.40% | -6.12% | 4.30% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
58 Neutral | £4.44M | 10.33 | 25.71% | ― | 17.91% | 73.21% | |
53 Neutral | £89.45M | -6.09 | -11.22% | 12.88% | -14.31% | -361.93% | |
40 Underperform | £12.36M | -1.54 | -29.38% | ― | -1.70% | -29.90% |
Norman Broadbent reported strong financial performance in Q3 2025, with a 26% increase in net fee income (NFI) compared to Q3 2024, reaching £2.9 million. The company is optimistic about future growth, having completed a business turnaround and improved its financial position. It plans to invest in headcount for organic growth and explore strategic inorganic growth opportunities to scale its operations.
The most recent analyst rating on (GB:NBB) stock is a Hold with a £203.00 price target. To see the full list of analyst forecasts on Norman Broadbent stock, see the GB:NBB Stock Forecast page.